Business Context and Reporting Period
OSI Systems, Inc. designs and manufactures specialized electronic systems and components for homeland security, healthcare, defense and aerospace markets. Its three operating divisions are Security, Healthcare, and Optoelectronics and Manufacturing.
The filing is an audited Form 10-K for the fiscal year ended June 30, 2015, filed August 24, 2015. The request metadata references 2014 Q4; the filing includes unaudited fourth-quarter results for the quarter ended June 30, 2015, compared with June 30, 2014.
- Security revenue: $481.1 million, approximately 50% of consolidated revenue.
- Healthcare revenue: $255.7 million, approximately 27%.
- Optoelectronics and Manufacturing external revenue: $221.4 million, approximately 23%.
Financial Performance and Key Metrics
| Metric | Fiscal 2015 | Fiscal 2014 | Change |
|---|---|---|---|
| Revenue | $958.2 million | $906.7 million | 6% |
| Gross profit | $325.4 million | $305.0 million | 7% |
| Gross margin | 34.0% | 33.6% | +0.4 percentage points |
| Operating income | $92.1 million | $81.3 million | 13% |
| Net income | $65.2 million | $47.9 million | 36% |
| Diluted EPS | $3.17 | $2.33 | 36% |
| Effective tax rate | 26.7% | 36.9% | Lower by 10.2 points |
| Operating cash flow | $105.1 million | $129.2 million | Down 19% |
| Capital expenditures | $15.3 million | $54.6 million | Down 72% |
Fiscal 2015 revenue growth was led by Security, including approximately $48 million of incremental revenue from a Foreign Military Sale contract for cargo and vehicle inspection systems for Iraq. Healthcare revenue increased 15%, supported by improved North American sales, new products and a European cardiology acquisition. Optoelectronics and Manufacturing revenue decreased 9% because of lower contract manufacturing sales to two major customers.
SG&A increased 3% to $171.8 million, while R&D increased 15% to $51.6 million, primarily reflecting investment in next-generation Security products. Impairment, restructuring and other charges declined to $9.8 million from $12.0 million and included $3.8 million of government-contract-related costs and $0.7 million of litigation defense costs.
Cash and cash equivalents were $47.6 million at June 30, 2015, compared with $38.8 million at June 30, 2014. Total debt was $11.4 million, down from $37.3 million. No borrowings were outstanding under the $450 million revolving credit facility, although $6.0 million of letters of credit were outstanding. Working capital was $292.2 million.
The company used cash for $20.1 million of acquisitions and other assets, $37.9 million of common-stock repurchases and net share settlements, and $24.0 million of debt repayments. Approximately 63% of cash was held by foreign subsidiaries and subject to repatriation tax considerations.
Fourth-Quarter Results
| Metric | Quarter Ended June 30, 2015 | Quarter Ended June 30, 2014 |
|---|---|---|
| Revenue | $266.6 million | $260.1 million |
| Gross profit | $89.2 million | $85.6 million |
| Operating income | $30.9 million | $30.8 million |
| Net income | $22.4 million | $22.1 million |
| Diluted EPS | $1.09 | $1.07 |
Material Changes Versus the Prior Comparable Period
- Consolidated revenue increased 6%, while operating income increased 13%.
- Healthcare became a larger, higher-margin contributor, and lower Optoelectronics and Manufacturing revenue improved consolidated gross margin.
- Operating cash flow declined because fiscal 2014 benefited from unusually strong collections and deferred revenue related to the Mexico turnkey program.
- Capital spending declined materially as Mexico turnkey-program investment moderated.
- Debt declined by $25.9 million, and the company repurchased 454,635 shares during fiscal 2015.
- Backlog declined to approximately $0.6 billion from $0.8 billion, primarily as the large Mexico turnkey program was converted into recognized revenue.
- The lower tax rate principally reflects the absence of the $7.6 million non-cash tax charge recorded in fiscal 2014 for accelerated depreciation of Mexico-related assets. Excluding that charge, the fiscal 2014 effective tax rate was approximately 26.8%, broadly comparable with fiscal 2015.
Outlook, Risks, Contingencies and Unusual Items
Management expects available cash, operating cash flow and credit facilities to satisfy operational needs for the foreseeable future. The filing does not provide numerical revenue or earnings guidance.
- Backlog is not considered a reliable indicator of future-period revenue because delivery timing, customer acceptance, product mix and cancellations can vary.
- The company remains exposed to government budget reductions, sequestration, contract delays, export controls and the possibility that government contracts may be terminated or modified for convenience.
- The company is performing a 10-year turnkey contract for Puerto Rico’s Ports Authority; management warned that Puerto Rico’s fiscal condition could affect payments.
- The Healthcare division received an FDA warning letter in August 2014 concerning procedures and internal processes at its Snoqualmie, Washington facility. Corrective actions were implemented, but additional regulatory action, including restrictions, fines, seizure or recall, remains possible.
- A securities class action settlement of $15.0 million was agreed after fiscal year-end and remained subject to court approval and other conditions. The company expects insurance to fund the settlement. Related shareholder derivative actions remained unresolved, with outcomes not reasonably estimable.
- The TSA contract dispute arising from use of an unapproved upgraded X-ray generator was resolved by mutual agreement in April 2015.
- The company continues to investigate historical soil and groundwater contamination at its Hawthorne, California facility. No environmental liability was accrued because management did not consider a loss probable and reasonably estimable.
- Contingent acquisition payments had a maximum potential amount of $37.3 million, with $17.2 million recorded on the balance sheet at June 30, 2015.
- Customer concentration, single-source suppliers, foreign currency exposure, cybersecurity, product liability, medical-device regulation, litigation and execution of the Mexico program remain material risks.
Most Important Facts for Investors to Verify
- Whether the Healthcare growth rate and improved mix are sustainable after the European cardiology acquisition.
- The quality and timing of Security revenue tied to government and international contracts, including the Iraq FMS contract and Mexico turnkey program.
- Backlog conversion, new order intake and the reasons for the decline from approximately $0.8 billion to $0.6 billion.
- The status and financial impact of the FDA warning letter and any related remediation, recall or operating restrictions.
- Final approval, insurance funding and cash-flow impact of the $15.0 million securities class action settlement, as well as the outcome of derivative litigation.
- Future cash requirements for contingent acquisition obligations, contractual commitments, stock repurchases and foreign cash repatriation.
- Exposure to currency movements; management estimated that a 10% appreciation or depreciation of the U.S. dollar could change fiscal 2015 operating income by approximately $14.0 million in the opposite direction.
- The filing reports effective disclosure controls and internal control over financial reporting, with an unqualified audit opinion; investors should nevertheless review subsequent filings for developments after June 30, 2015.